Publications by authors named "Nicholas Restifo"

Claim this Profile
T
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee.
George Coukos, Marco Donia, Brian R Gastman, Stephanie L Goff, Alena Gros, Nicholas P Restifo

J Immunother Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regenerative Immunotherapy for Cancer: Transcription Factor Reprogramming of Tumor-Specific T Cells.
Tyler R McCaw, Nicholas P Restifo, Kathrin Plath, Joseph G Crompton

Cancers (Basel)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T cells lead the charge against solid tumors.
Rigel J Kishton, Nicholas P Restifo

Nat Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LIM-domain-only 4 (LMO4) enhances CD8 T-cell stemness and tumor rejection by boosting IL-21-STAT3 signaling.
Roland C Schelker, Jessica Fioravanti, Fabio Mastrogiovanni, Jeremy G Baldwin, Nisha Rana, Nicholas P Restifo

Signal Transduct Target Ther· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic soldiers: Turning T cells into immortal warriors.
Nicholas P Restifo, Luca Gattinoni

J Exp Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells.
S M Rafiqul Islam, Takuya Maeda, Naritaka Tamaoki, Meghan L Good, Rigel J Kishton, Nicholas P Restifo

Cancer Res Commun· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Self-organized yolk sac-like organoids allow for scalable generation of multipotent hematopoietic progenitor cells from induced pluripotent stem cells.
Naritaka Tamaoki, Stefan Siebert, Takuya Maeda, Ngoc-Han Ha, Meghan L Good, Nicholas P Restifo

Cell Rep Methods· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fine-tuning T cell function through engineered orthogonal chimeric cytokine receptors.
Rigel J Kishton, Nicholas P Restifo

Cell Res· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade.
Douglas C Palmer, Beau R Webber, Yogin Patel, Matthew J Johnson, Christine M Kariya, Nicholas P Restifo

Med· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer genes disfavoring T cell immunity identified via integrated systems approach.
Rigel J Kishton, Shashank J Patel, Amy E Decker, Suman K Vodnala, Maggie Cam, Nicholas P Restifo

Cell Rep· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next generation immunotherapy: enhancing stemness of polyclonal T cells to improve anti-tumor activity.
Rigel J Kishton, Suman K Vodnala, Raul Vizcardo, Nicholas P Restifo

Curr Opin Immunol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An engineered IL-2 partial agonist promotes CD8 T cell stemness.
Fei Mo, Zhiya Yu, Peng Li, Jangsuk Oh, Rosanne Spolski, Nicholas P Restifo

Nature· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiply restimulated human thymic regulatory T cells express distinct signature regulatory T-cell transcription factors without evidence of exhaustion.
Keli L Hippen, Scott N Furlan, Rahul Roychoudhuri, Ena Wang, Yigang Zhang, Nicholas P Restifo

Cytotherapy· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
STING agonist promotes CAR T cell trafficking and persistence in breast cancer.
Nuo Xu, Douglas C Palmer, Alexander C Robeson, Peishun Shou, Hemamalini Bommiasamy, Nicholas P Restifo

J Exp Med· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy.
Eva Pérez-Guijarro, Howard H Yang, Romina E Araya, Rajaa El Meskini, Helen T Michael, Nicholas P Restifo

Nat Med· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas.
Devin Dersh, James D Phelan, Megan E Gumina, Boya Wang, Jesse H Arbuckle, Nicholas P Restifo

Immunity· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Definitive hematopoietic stem/progenitor cells from human embryonic stem cells through serum/feeder-free organoid-induced differentiation.
Selami Demirci, Juan J Haro-Mora, Alexis Leonard, Claire Drysdale, Daniela Malide, Nicholas P Restifo

Stem Cell Res Ther· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definitive hematopoietic stem/progenitor cells from human embryonic stem cells through serum/feeder-free organoid-induced differentiation.
Selami Demirci, Juan J Haro-Mora, Alexis Leonard, Claire Drysdale, Daniela Malide, Nicholas P Restifo

Stem Cell Res Ther· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strength in Numbers: Identifying Neoantigen Targets for Cancer Immunotherapy.
Rigel J Kishton, Rachel C Lynn, Nicholas P Restifo

Cell· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies.
Devikala Gurusamy, Amanda N Henning, Tori N Yamamoto, Zhiya Yu, Nikolaos Zacharakis, Nicholas P Restifo

Cancer Cell· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy.
Eva Pérez-Guijarro, Howard H Yang, Romina E Araya, Rajaa El Meskini, Helen T Michael, Nicholas P Restifo

Nat Med· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens.
Parisa Malekzadeh, Rami Yossef, Gal Cafri, Biman C Paria, Frank J Lowery, Nicholas P Restifo

Clin Cancer Res· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Small Molecule Enhancers of Immunotherapy for Melanoma.
Christopher Dextras, Myagmarjav Dashnyam, Lesley A Mathews Griner, Janani Sundaresan, Bryan Chim, Nicholas P Restifo

Sci Rep· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models.
Ling Zhang, John S Davies, Carylinda Serna, Zhiya Yu, Nicholas P Restifo

J Immunother Cancer· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying the source of tumour-infiltrating T cells.
Suman Kumar Vodnala, Nicholas P Restifo

Nature· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis